DOCSLIB.ORG

Malaysian Journal of Pharmacy Vol.4 Issue 1, July 2018 ______

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Malaysian Journal of Pharmacy Vol.4 Issue 1, July 2018 ______ Vol. 2 Issue 2. August 2016 Vol.4 Issue 1. July 2018 MALAYSIANMALAYSIAN JOURNALJOURNALof ofPHARMACY PHARMACY Supplement: Proceedingsofthe9th National Pharmacy R&D In this issue:Conference 2016 Serial Drama: Seven Steps to Avoid Falling Foul of Falsified Medicines Directive (FMD) Management of Mild Valproic Acid Toxicity with Hemodialysis – A Case Report Stability of Extemporaneously Compounded Chloral Hydrate Oral Solution Supplement Proceedings of the 10th National Pharmacy R&D Conference 2018 APublicationoftheMalaysianPharmaceuticalSociety EDITORIAL BOARD A Publication of the Malaysian Pharmaceutical Society Malaysian Journal of Pharmacy Vol.4 Issue 1, July 2018 ___________________________________________________________________ The Official Journal of the Malaysian Pharmaceutical Society Editor-in-Chief: Assoc. Prof. Dr. Asrul Akmal Shafie Managing Editor: Mr. Ho Rhu Yann International Advisory Board: Assoc. Prof. Dr. Chua Siew Siang Prof. Dr. Mohd Baidi Bahari Associate Editors: Mr. Lam Kai Kun Prof. Dr. Mohamed Azmi Ahmad Hassali Assoc. Prof. Dr. Mohamad Haniki Nik Mohamed Ms. Syireen Alwi Prof. P T Thomas Dr. Wong Tin Wui Assoc. Prof. Dr. Vikneswaran a/l Murugaiyah Prof. Dr. Yuen Kah Hay Publisher: Malaysian Pharmaceutical Society 16-2 Jalan OP 1/5, 1-Puchong Business Park Off Jalan Puchong 47160 Puchong Malaysia Tel: 6-03-80791861 Fax: 6-03-80700388 Homepage: www.mps.org.my Email: [email protected] The Malaysian Journal of Pharmacy is a publication of the Malaysian Pharmaceutical Society. Enquiries are to be directed to the publisher at the above address. The Publisher reserves copy- right and renewal on all published materials, and such material may not be reproduced in any form without the written permission of the Publisher. ISSN 1675-3666 9 771675 366005 Table of Contents Editorial Research papers Serial drama: seven steps to avoid falling foul of falsified medicines directive (FMD) Management of mild valproic acid toxicity with hemodialysis – a case report Stability of extemporaneously compounded chloral hydrate oral solution Acknowledgement Reviewers of abstracts List of oral presentations Abstracts of oral presentations List of poster presentations Abstracts of poster presentations Editorial ENHANCING ACCESS TO MEDICINES THROUGH VALUE-BASED APPROACHES Abdul Haniff b Mohamad Yahaya, PhD Department of Pharmacy, Hospital Teluk Intan, Perak, Ministry of Health Malaysia In the last decade, value has played a key role in healthcare system. The value-based approach refers to a personalized care, where patient’ expectations and needs are included in a holistic approach of medicine that considers physical, mental, and spiritual well-being1. Nowadays, the paradigm has shifted from evidence-based medicine (EBM) to value-based medicines (VBM). The term “value-based” was first introduced by Brown et al as “the practice of medicines incorporating the highest level of evidence-based data with patient perceived value conferred by healthcare interventions for the resource expended”2. The aim of introduction of VBM is to improve the quality of healthcare by efficient utilization of resources. The key principle in VBM is the integration between best clinical evidence and patient preferences in the decision making process. Therefore, there are needs for changes in point of views between healthcare providers and patients. As healthcare management is clearly moving towards patient-centered system, we should emphasize on the patients’ empowerment. This enables the patients to be an active and effective participant in their own process of care and to be part of the decision. Thus, the utilization of healthcare especially the access to medicines could be enhanced. Our National Medicines Policy (2012) emphasizes on the improvement of access to medicines for the patients. The equitable access and rational use of safe, effective and affordable good quality essential medicines to improve health outcomes of the population are the main objective of the policy. In addition, it emphasizes the quality use of medicines by patients’ empowerment on the information. This indirectly sets up a platform to initiate the implementation of VBM. However, the resources are still lacking in terms of research especially this country, to enable the success of the implementation of VBM. Research in patients’ preferences coupled with clinical expertise is fundamental towards a value-based system. The current emerging trend in research has captivated pharmacy profession to shift their focus to “Enhancing Access to Medicines through Value-based Approaches”. This issue of Malaysian Journal of Pharmacy encompasses the collection of abstract proceedings that is presented either as oral or poster presentation at the 10th National Pharmacy R&D Conference on 9 – 11 July 2018. On behalf of the scientific committee, I would like to express my sincerest gratitude to all pharmacist researchers who have shown immense passion by submitting their interesting research findings for us. 1Marzorati C, Pravettoni G. Value as a concept in the health care system. Journal of Multidisciplinary Healthcare 2017;10: 101-106 2Brown MM, Brown GC, Sharma S. Evidence-based to value-based medicine. Chicago: AMA Press; 2005, p. 5- 7, 125-149, 151-181, 193-217, 267-279, 319-324 SERIAL DRAMA: SEVEN STEPS TO AVOID FALLING FOUL OF FALSIFIED MEDICINES DIRECTIVE (FMD) Davison M* rfxcel Corporation, 12667 Alcosta Boulevard, Suite 375, San Ramon, California 94583, the United States of America. *Author for correspondence INTRODUCTION The Falsified Medicines Directive (FMD) imposes strict serialisation requirements on pharmaceutical manufacturers, distributors and dispensers. This article outlines everything you need to know and what you need to do for a seamless serialisation process – before regulators remove your right to trade. Pharmaceutical manufacturers are currently the main actors in a serial drama where getting their lines right is paramount. Well, four lines of data, to be precise; in (and next to) DataMatrix barcodes applied to every pack of prescription medicines. The introduction of serialisation, designed to ensure the authenticity and traceability of individual medicines, promises to improve patient safety and create exciting opportunities for digital health. But there is a twist in the plot. Failure to comply with the EU regulation that mandates it means you cannot legally ship your product. No barcode, no trade. That is when a serial drama turns into a tragedy. And time is running out to be ready. The unfolding story of the Falsified Medicines Directive (FMD), which was first introduced in 2011, is into its final episodes. The denouement arrives on February 9, 2019, when the Directive is fully enforced and the penalties for non-compliance officially come into play. FMD is an attempt to prevent inauthentic, substandard or harmful medicines entering the supply chain. It imposes strict serialisation, traceability and verification requirements on pharmaceutical manufacturers and their associated wholesalers, distributors and contract manufacturers. In particular, it mandates companies to print a unique identifier on the packaging of prescription medicines. Furthermore, companies are not just responsible for the data that goes on the packaging, they are responsible for submitting it to the central data hub that will enable pharmacists to authenticate products before they dispense them. It is a complex undertaking that could be easily underestimated - but not if you understand some key steps. The implementation of serialisation is not an overnight task – it encompasses processes that have multiple touch-points across global organisations, partner networks and the wider supply chain. Yet despite this – and despite the enormous implications of getting it wrong – many companies are still some distance from being fit for purpose. Indeed, in some organisations, the Directive has not yet hit their radar. It needs to – because the clock is ticking. But all is not lost. Here are seven steps to successful serialisation. 1: GET EXECUTIVE BUY-IN The significance of serialisation is often underestimated. It is typically considered a production issue and punted to manufacturing as an operational challenge. Yet serialisation is a board level issue, with ramifications that could directly affect business performance. Indeed, it is not a manufacturing cost – it is a business continuity risk that touches every aspect of an organisation. So the first step towards serialisation – one that is often overlooked – is to appoint an executive sponsor, ideally with board level oversight, to lead a holistic strategy. Implementation will naturally be delegated to project teams, but executive leadership will be crucial to making things happen quickly. 2: ASSEMBLE A MULTI-DISCIPLINARY TEAM Multi-disciplinary engagement is essential. Many organisations do not understand all their business processes in sufficient detail to overlay serialisation. It is therefore vital that a multi- disciplinary team (MDT) is convened at the earliest opportunity to map the process flow of the business and establish a roadmap of how serialisation can be applied across multiple organisational boundaries. An MDT should actively engage representatives from manufacturing, supply chain, information technology, legal/regulatory and partner/contract management. 3: ESTABLISH LONG-TERM USER REQUIREMENTS TO ENSURE YOU RE ‘FUTURE READY’ The next step is to define your user requirements and establish a template for the solution that will
Load more

Recommended publications
  • Abstracts of the 16Th Annual Scientific Meeting of the College Of
    Malaysian J Pathol 2018; 40(1) : 83 – 102 The 16th Annual Scientific Meeting of the College of Pathologists, Academy of Medicine of Malaysia was held at the Royale Chulan Seremban Hotel, in Seremban, Negeri Sembilan on 12th- 13th October 2017. Abstracts of paper (poster) presented are as follows: AP-01. A palatal swelling transpires out as a nasal B-cell NHL- a case report Sunil Pazhayanur Venkateswaran1, Rafiq Abdul Karim Vasiwala2 Department of Pathology1 and ENT2, International Medical University, Kuala Lumpur, Malaysia Introduction: Primary sinonasal Non-Hodgkin’s Lymphoma’s (NHLs) is a rare condition, which emulates the presentation of a benign inflammatory disease. It is challenging to distinguish morphologically as well as radiologically sinonasal lymphomas from other malignant neoplasms. Case Report: We report a 37-year-old male patient who was presented with nasal obstruction, rhinorrhoea, bloody discharge/epistaxis, post nasal drip, facial swelling, orbital symptoms and fever. Endoscopic examination and CT scan of the paranasal sinuses with adequate amount of biopsy tissue is required for a definitive diagnosis. Considering this, endoscopic sinus surgery was performed to eradicate the disease as well as obtain a definite histological diagnosis. The mass was histologically proven as a Nasal diffuse large B-cell lymphoma(DLBCL) and confirmed by immunohistochemistry. Immunohistochemically, the cells were strongly positive for CD20, CD79a, BCL2, BCL6 and MUM1.CD10 was focally positive. Ki-67 index was <99%. After confirmation of the histological diagnosis, chemotherapy was started and with the first cycle, the patient improved with resolution of the facial swelling as well as pain and visual defects. Conclusion: The diagnosis of a sinonasal lymphoma is a challenge for otorhinologists.
    [Show full text]
  • Selective Screening for Gestational Diabetes in Malaysia
    Ganeshan Muniswaran1, H Suharjono1, SA Soelar2, SD Karalasingam2, R Jeganathan3 Sarawak General Hospital, 1-Sarawak General Hospital, Kuching, Sarawak, Malaysia Jalan Hospital, 93586, Kuching, Sarawak 2- Clinical Research Centre, Kuala Lumpur, Malaysia Hp. No: 0125871220 3- Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia Email: [email protected] INTRODUCTION Gestational Diabetes is common in Malaysia and has significant maternal and fetal implications. Active intervention has shown to improve pregnancy outcomes. Pregnancy is an opportunistic time for screening as the future implications of Diabetes can be significant. An ideal screening tool should not be based on complications of the disease or following an adverse event. Despite recommendations for universal screening in a high risk population, Malaysia has opted for selective screening, due to concerns with cost and resources. The objective is to review the effectiveness of the current practice of selective screening for GDM in Malaysia. METHODOLOGY This is a retrospective cohort study. The study period was from 1st January 2011 till 31st December 2012 and 22, 044 patients with GDM were analyzed. Specific variables were extracted from the National Obstetric Registry of Malaysia from all the participating hospitals, with a total 260,959 patients. RESULTS The incidence of GDM is 8.4%. Majority of these patients were identified following GDM complications such as fetal macrosomia, polyhydramnios or increased weight gain. GESTATIONAL DIABETES CRUDE OR VARIABLE YES NO (SIMPLE
    [Show full text]
  • The Provider-Based Evaluation (Probe) 2014 Preliminary Report
    The Provider-Based Evaluation (ProBE) 2014 Preliminary Report I. Background of ProBE 2014 The Provider-Based Evaluation (ProBE), continuation of the formerly known Malaysia Government Portals and Websites Assessment (MGPWA), has been concluded for the assessment year of 2014. As mandated by the Government of Malaysia via the Flagship Coordination Committee (FCC) Meeting chaired by the Secretary General of Malaysia, MDeC hereby announces the result of ProBE 2014. Effective Date and Implementation The assessment year for ProBE 2014 has commenced on the 1 st of July 2014 following the announcement of the criteria and its methodology to all agencies. A total of 1086 Government websites from twenty four Ministries and thirteen states were identified for assessment. Methodology In line with the continuous and heightened effort from the Government to enhance delivery of services to the citizens, significant advancements were introduced to the criteria and methodology of assessment for ProBE 2014 exercise. The year 2014 spearheaded the introduction and implementation of self-assessment methodology where all agencies were required to assess their own websites based on the prescribed ProBE criteria. The key features of the methodology are as follows: ● Agencies are required to conduct assessment of their respective websites throughout the year; ● Parents agencies played a vital role in monitoring as well as approving their agencies to be able to conduct the self-assessment; ● During the self-assessment process, each agency is required to record
    [Show full text]
  • Comparison of the Treatment Practice And
    RESEARCH ARTICLE Comparison of the treatment practice and hospitalization cost of percutaneous coronary intervention between a teaching hospital and a general hospital in Malaysia: A cross sectional study Kun Yun Lee1*, Wan Azman Wan Ahmad2, Ee Vien Low3, Siow Yen Liau4,5, a1111111111 Lawrence Anchah6, Syuhada Hamzah7, Houng-Bang Liew5,8, Rosli B. Mohd Ali9, a1111111111 Omar Ismail10, Tiong Kiam Ong11, Mas Ayu Said1, Maznah Dahlui1 a1111111111 a1111111111 1 Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2 Division of Cardiology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala a1111111111 Lumpur, Malaysia, 3 Pharmaceutical Services Division, Ministry of Health, Selangor, Malaysia, 4 Department of Pharmacy, Queen Elizabeth 2 Hospital, Sabah, Malaysia, 5 Clinical Research Centre, Queen Elizabeth 2 Hospital, Sabah, Malaysia, 6 Department of Pharmacy, Sarawak General Hospital Heart Centre, Sarawak, Malaysia, 7 Administrative Office, Penang General Hospital, Penang, Malaysia, 8 Division of Cardiology, Queen Elizabeth 2 Hospital, Sabah, Malaysia, 9 Department of Cardiology, National Heart Institute, Kuala Lumpur, Malaysia, 10 Division of Cardiology, Penang General Hospital, Penang, Malaysia, 11 Department of OPEN ACCESS Cardiology, Sarawak General Hospital Heart Centre, Sarawak, Malaysia Citation: Lee KY, Wan Ahmad WA, Low EV, Liau SY, Anchah L, Hamzah S, et al. (2017) Comparison * [email protected] of the treatment practice and hospitalization cost of percutaneous coronary intervention between a teaching hospital and a general hospital in Abstract Malaysia: A cross sectional study. PLoS ONE 12 (9): e0184410. https://doi.org/10.1371/journal. pone.0184410 Editor: Yoshihiro Fukumoto, Kurume University Introduction School of Medicine, JAPAN The increasing disease burden of coronary artery disease (CAD) calls for sustainable car- Received: May 15, 2017 diac service.
    [Show full text]
  • 300512 CPG Management of Stroke Copy
    I CLINICAL PRACTICE GUIDELINES DEVELOPMENT GROUP AUTHORS (in alphabetical order) PROF DR HAMIDON BASRI Consultant Neurologist Chairperson University Putra Malaysia, Selangor A/PROF DR CHIN SZE PIAW Consultant Cardiologist International Medical University, KL DR LOOI IRENE Consultant Neurologist Hospital Seberang Jaya, Penang DR MAK CHOON SOON Consultant Neurologist Gleneagles Hospital, KL A/PROF DR MOHAMED SOBRI MUDA Consultant Neuroradiologist University Kebangsaan Malaysia Medical Centre, KL DATO’ DR MD. HANIP RAFIA Consultant Neurologist Hospital Kuala Lumpur, KL PROF DR TAN KAY SIN Consultant Neurologist University Malaya Medical Centre, KL DR ZARIAH ABDUL AZIZ Consultant Neurologist Hospital Sultanah Nur Zahirah, Terengganu EXTERNAL REVIEWERS (in alphabetical order) DR HJ BAHANORDIN BIN JAAFAR Physician of Rehabilitation Medicine Hospital Serdang, Selangor PROF DR GOH KHEAN JIN Consultant Neurologist University Malaya Medical Centre, KL DATO’ DR LOH THIAM GHEE Consultant Neurologist Sime Darby Medical Centre, Selangor DATO’ DR MOHD RANI JUSOH Consultant Neurologist Ampang Puteri Hospital, KL DATO’ DR MUHAMMAD RADZI BIN ABU HASSAN Consultant Physician Hospital Sultanah Bahiyah, Kedah ASSOC PROF DR NOOR AZAH ABD AZIZ Family Medicine Specialist University Kebangsaan Malaysia Medical Center, KL PROF DATO’ DR RAYMOND AZMAN ALI Consultant Neurologist University Kebangsaan Malaysia Medical Centre, KL PROF DR TAN CHONG TIN Consultant Neurologist University Malaya Medical Centre, KL II RATIONALE AND PROCESS OF GUIDELINE DEVELOPMENT Rationale Stroke is a leading cause of death and disability in Malaysia. Thus, guidelines on the management are imperative to ensure best available therapy is instituted. The clinical practice guidelines (CPG) on ischaemic stroke was developed to provide clear and concise approach to all clinicians on the current concepts in the management of ischaemic stroke patients.
    [Show full text]
  • Auditor General's Report 2015
    AUDITOR GENERAL’S REPORT 2015 NATIONAL AUDIT DEPARTMENT MALAYSIA GOVERNMENT’S FINANCIAL STATEMENT, FINANCIAL MANAGEMENT No. 15, Level 1-5 FOR THE YEAR 2015 AND ACTIVITIES OF THE Persiaran Perdana, Presint 2 Pusat Pentadbiran Kerajaan Persekutuan FEDERAL MINISTRIES/DEPARTMENTS AND 62518 Putrajaya MANAGEMENT OF THE GOVERNMENT’S COMPANIES www.audit.gov.my SERIES 1 NATIONAL AUDIT DEPARTMENT MALAYSIA WJHS00124 Cover.indd 1 WJHS00124 T.page.indd 11 5/13/165/13/16 3:354:18 PMPM SYNOPSIS AUDITOR GENERAL’S REPORT FOR THE YEAR 2015 THE AUDIT OF THE FEDERAL GOVERNMENT’S FINANCIAL STATEMENT, FINANCIAL MANAGEMENT, ACTIVITIES OF THE FEDERAL MINISTRIES/DEPARTMENTS AND MANAGEMENT OF THE GOVERNMENT COMPANIES NATIONAL AUDIT DEPARTMENT MALAYSIA i WJHS00124 T.page.indd 1 5/13/16 2:53 PM CONTENTS iii WJHS00124 T.page.indd 2 5/13/16 2:53 PM CONTENTS iii WJHS00124 T.page.indd 3 5/13/16 2:53 PM CONTENTS PAGE CONTENTS v SECTION I THE FEDERAL GOVERNMENT’S FINANCIAL STATEMENT AND FINANCIAL MANAGEMENT OF THE FEDERAL MINISTRIES/DEPARTMENTS PREFACE 5 SYNOPSIS 13 PART I CERTIFICATION OF THE FEDERAL GOVERNMENT‟S FINANCIAL STATEMENT FOR THE YEAR ENDED 31ST DECEMBER 2015 1. Certification Of The Federal Government‟s Financial Statement For The Year Ended 31st December 2015 15 PART II FINANCIAL MANAGEMENT OF THE FEDERAL GOVERNMENT 2. Overall Financial Management Performance 15 3. Financial Management Of The Federal Ministries And Departments 16 4. Public Accounts Committee Meeting 17 CONCLUSION 19 v WJHS00124 T.page.indd 4 5/13/16 2:53 PM CONTENTS PAGE CONTENTS v SECTION I THE FEDERAL GOVERNMENT’S FINANCIAL STATEMENT AND FINANCIAL MANAGEMENT OF THE FEDERAL MINISTRIES/DEPARTMENTS PREFACE 5 SYNOPSIS 13 PART I CERTIFICATION OF THE FEDERAL GOVERNMENT‟S FINANCIAL STATEMENT FOR THE YEAR ENDED 31ST DECEMBER 2015 1.
    [Show full text]
  • Malaysia Health System Review Health Systems in Transition Vol
    Health Systems in Transition Vol. 2 No. 1 2012 Vol. in Transition Health Systems Health Systems in Transition Vol. 3 No.1 2013 Malaysia Health System Review The Asia Pacific Observatory on Health Review Malaysia Health System Systems and Policies is a collaborative partnership which supports and promotes evidence-based health policy making in the Asia Pacific Region. Based in WHO’s Regional Office for the Western Pacific it brings together governments, international agencies, foundations, civil society and the research community with the aim of linking systematic and scientific analysis of health systems in the Asia Pacific Region with the decision- makers who shape policy and practice. Asia Pacific Observatory on Health Systems and Policies Health Systems in Transition Vol. 3 No. 1 2013 Malaysia Health System Review Written by: Safurah Jaafar, Ministry of Health, Malaysia Kamaliah Mohd Noh, Ministry of Health, Malaysia Khairiyah Abdul Muttalib, Ministry of Health, Malaysia Nour Hanah Othman, Ministry of Health, Malaysia Judith Healy, Australian National University, Australia Other authors: Kalsom Maskon, Ministry of Health, Malaysia Abdul Rahim Abdullah, Ministry of Health, Malaysia Jameela Zainuddin, Ministry of Health, Malaysia Azman Abu Bakar, Ministry of Health, Malaysia Sameerah Shaikh Abd Rahman, Ministry of Health, Malaysia Fatanah Ismail, Ministry of Health, Malaysia Chew Yoke Yuen, Ministry of Health, Malaysia Nooraini Baba, Ministry of Health, Malaysia Zakiah Mohd Said, Ministry of Health, Malaysia Edited by: Judith Healy, Australian National University, Australia WHO Library Cataloguing in Publication Data Malaysia health system review. (Health Systems in Transition, Vol. 2 No. 1 2012) 1. Delivery of healthcare. 2. Health care economics and organization.
    [Show full text]
  • Malaysian Statistics on Medicines 2009 & 2010
    MALAYSIAN STATISTICS ON MEDICINES 2009 & 2010 Edited by: Siti Fauziah A., Kamarudin A., Nik Nor Aklima N.O. With contributions from: Faridah Aryani MY., Fatimah AR., Sivasampu S., Rosliza L., Rosaida M.S., Kiew K.K., Tee H.P., Ooi B.P., Ooi E.T., Ghan S.L., Sugendiren S., Ang S.Y., Muhammad Radzi A.H. , Masni M., Muhammad Yazid J., Nurkhodrulnada M.L., Letchumanan G.R.R., Fuziah M.Z., Yong S.L., Mohamed Noor R., Daphne G., Chang K.M., Tan S.M., Sinari S., Lim Y.S., Tan H.J., Goh A.S., Wong S.P., Fong AYY., Zoriah A, Omar I., Amin AN., Lim CTY, Feisul Idzwan M., Azahari R., Khoo E.M., Bavanandan S., Sani Y., Wan Azman W.A., Yusoff M.R., Kasim S., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Suganthi T., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I, Wan Hamilton W.H., Zaridah S., Maisarah A.H., Rohan Malek J., Selvalingam S., Lei C.M., Hazimah H., Zanariah H., Hong Y.H.J., Chan Y.Y., Lin S.N., Sim L.H., Leong K.N., Norhayati N.H.S, Sameerah S.A.R, Rahela A.K., Yuzlina M.Y., Hafizah ZA ., Myat SK., Wan Nazuha W.R, Lim YS,Wong H.S., Rosnawati Y., Ong S.G., Mohd. Shahrir M.S., Hussein H., Mary S.C., Marzida M., Choo Y. M., Nadia A.R., Sapiah S., Mohd. Sufian A., Tan R.Y.L., Norsima Nazifah S., Nurul Faezah M.Y., Raymond A.A., Md.
    [Show full text]
  • T Study on JICA's Technical Cooperation to Malaysia Volume 2
    ~ t Study on JICA's Technical Cooperation to Malaysia Volume 2 J l 1 1 1 .s·~ ·. l JICAJ l l l l l Asset Study on JICA's Technical Cooperation to Malaysia I Volume 2 I J Final Report J J J J ~~~i, :C'<"' "'~ ."' ~,.., ,v~',;;/;} ,"'~,_;•A 0 f•0w,\" " ' r ,E Researc lit ·."·', ~\\ < 't'-.. -~!St "'": ~»v,;,s:"', ~< J Plannjng~ Econ~~C2 nsultan_1s PE Research 5dn Bhd J 1338 Jalan 5525/2, Taman Mewah 47301 Petaling Jaya, 5elangor Darul Ehsan, Malaysia J www.peresearch.com.my November 2009 J J I [ I -] l f' [l [ 8 [l u L: IJ ( ~ :J 0 0 0 0 0 0 c c L u u 1 1 Asset Study on JlCA's Technical Cooperation to Malaysia: Volume 2 l Table of Content l ACRONYMS ............................................................................................................................... Ill INTRODUCTION ........................................................................................................................... 1 1 1. AGRICULTURE, FORESTRY AND FISHERIES ...................................................................... 1-1 1.1 Ministry of Agriculture and Agro-Based Industry .......... .... ........................ .. ...... .. .. 1-1 l 1.1.1 Department of Agriculture (DOA) ................ ............................... ................. 1-3 1.1.2 Department of Fisheries (DOF) ...... .... ............................. ................ .......... 1-11 1.1.3 Department of Veterinary Services (DVS) .... .. ..... ............................... .. .. .. 1-18 l 1.1.4 Veterinary Research Institute (VRI) .... .... .. ...............................................
    [Show full text]
  • Journal of the ASEAN Federation of Endocrine Societies
    Journal of the JournalASEAN of the Federation of ASEANEndocrine Federation Societies of EndocrineVolume No. 34 Special EditionSocieties | ISSN 2308-118x (Online) Vol. 32 No. 2 November 2017 | ISSN 0857-1074 | eISSN 2308-118x 2019 1| 0 Pre-Congress: 18 July 2019 Congress: 19 - 21 July 2019 Hilton & Le Méridien Kuala Lumpur, Malaysia The Journal of the ASEAN Federation of Endocrine Societies (JAFES) is an open-access, peer-reviewed, English language, medical and health science journal that is published two times a year by the ASEAN Federation of Endocrine Societies (AFES). Its editorial policies are aligned with the policies of the International Committtee of Medical Journal Editors (www.icmje.org). SIMPLIFYING THE COMPLEXITY OF ENDOCRINOLOGY JAFES welcomes manuscripts on all aspects of endocrinology and metabolism in the form of original articles, review articles, case reports, feature articles (clinical practice guidelines, clinical case seminars, clinical practice guidelines, book reviews, et cetera), editorials, letters to the Editor, brief communications and special announcements. Authors may include members and non-members of the AFES. Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of:Messages (1) Authorship Certification, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each Organisingauthor; (2) the Author Declaration & Scientific, that the article Committee represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere; (3) the Statement of Copyright Transfer [accepted manuscripts become the permanent property of the JAFES and are licensed Listwith an ofAttribution Faculty-Share Alike-Non-Commercial Creative Commons License.
    [Show full text]
  • Conjoint Ophthalmology Scientific Conference (COSC 2017)
    Artwork for the 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) Logo COSC 2017 (designed by Dr Aliff Irwan Cheong) The logo symbolizes: 1. “C” represents as the whole eye, and its fluidic and wave like angle shape, exhibit the conference main theme “Angles and Curves”. The inferior tail of the “C” crosses and twist towards the word 2017 represents the conference aim in achieving advancement in Ophthalmology especially in Malaysia. 2. “O” represents the cornea and pupil – exhibit the specialty of interest : Glaucoma & Cornea. 3. “7” signify in RED is a hallmark of conference by COSC 2017. 4. BLUE – Theme color for conference and shown with the year its being held 5. BLACK – Second theme color for conference and shown in the other structure of interest Front Cover Artwork (designed by Dr Tan Li Mun) 1. Image of Cornea and Kuala Lumpur City Centre (KLCC) - Signifies the theme of our conjoint "Angles and Curves" and the location of our event held in Kuala Lumpur 2. Image of Pupil and Iris on the background - Signifies the other parts of anterior segment of the eye. ii Foreword The 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) was held on 15-17 September 2017 at the Pullman Kuala Lumpur Bangsar, Kuala Lumpur. These Scientific Conferences have been held by the Malaysian Universities Conjoint Committee of Ophthalmology every year since 2011, and the theme for this year‟s meeting was „Angles and Curves - New Perspectives on Glaucoma and Cornea Management‟. The programme consisted of workshops, lectures and case discussions conducted by expert international and local speakers, and updated participants on latest developments in the two exciting fields.
    [Show full text]
  • Prevalence of Chronic Kidney Disease and Its Associated Factors in Malaysia
    Saminathan et al. BMC Nephrology (2020) 21:344 https://doi.org/10.1186/s12882-020-01966-8 RESEARCH ARTICLE Open Access Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross- sectional study Thamil Arasu Saminathan1* , Lai Seong Hooi2, Muhammad Fadhli Mohd Yusoff1, Loke Meng Ong3, Sunita Bavanandan4, Wan Shakira Rodzlan Hasani1, Esther Zhao Zhi Tan5, Irene Wong6, Halizah Mat Rifin1, Tania Gayle Robert1, Hasimah Ismail1, Norazizah Ibrahim Wong1, Ghazali Ahmad4, Rashidah Ambak1, Fatimah Othman1, Hamizatul Akmal Abd Hamid1 and Tahir Aris1 Abstract Background: The prevalence of chronic kidney disease (CKD) in Malaysia was 9.07% in 2011. We aim to determine the current CKD prevalence in Malaysia and its associated risk factors. Methods: A population-based study was conducted on a total of 890 respondents who were representative of the adult population in Malaysia, i.e., aged ≥18 years old. Respondents were randomly selected using a stratified cluster method. The estimated glomerular filtration rate (eGFR) was estimated from calibrated serum creatinine using the CKD-EPI equation. CKD was defined as eGFR < 60 ml/min/1.73m2 or the presence of persistent albuminuria if eGFR ≥60 ml/min/1.73m2. Results: Our study shows that the prevalence of CKD in Malaysia was 15.48% (95% CI: 12.30, 19.31) in 2018, an increase compared to the year 2011 when the prevalence of CKD was 9.07%. An estimated 3.85% had stage 1 CKD, 4.82% had stage 2 CKD, and 6.48% had stage 3 CKD, while 0.33% had stage 4–5 CKD.
    [Show full text]